Therapeutic Response

not KIT p.D816V status confers therapeutic sensitivity to Imatinib in patients with Aggressive Systemic Mastocytosis.

Statements

Source and description
Gleevec (imatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.
Gleevec (imatinib) [product monograph]. HC. Health Canada approved imatinib mesylate for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.